Amgen: The Blame Game
September 27, 2016 at 10:43 AM EDT
This morning, Amgen ( AMGN ) reported that its cancer drug Kyprolis failed to do what it hoped it would in a late-stage trial . RBC's Michael Yee and Judy Liu wonder if the design of the trial was to blame:
